1

- 1 Title: Evaluation of the accuracy of a multi-infection screening test based on a multiplex
- immunoassay targeting imported diseases common in migrant populations 2
- 3 **Running title:** Multi-infection screening by Luminex technology
- Authors 4

Ruth Aguilar^{#1}, PhD: Angeline Cruz^{#1}, MSc: Alfons Jiménez^{1,2}, PhD: Alex Almuedo¹, MSc: 5 Carme Roca Saumell^{3,4}, PhD; Marina Gigante Lopez⁵, MD; Oriol Gasch⁶, PhD; Gemma

6 Falcó⁷, MD; Ana Jiménez-Lozano⁸, PhD; Angela Martínez-Perez⁹, PhD; Consol Sanchez-7

Collado¹⁰, MD; Andrea Tedesco¹¹, MD; Manuel Carlos López¹², PhD; María Jesús Pinazo^{1,13}, 8

PhD; Thais Leonel¹⁴, MSc; Zeno Bisoffi¹¹, PhD, Prof; Anna Färnert^{15,16}, PhD, Prof; Carlota 9

Dobaño†^{1,13}, PhD Prof; Ana Requena-Méndez†^{1,13,15,16}, MD, PhD. 10

12	1.	Barcelona Institute for Global Health (ISGlobal), Hospital Clínic-Universitat de
13		Barcelona. Carrer Roselló 132, 08036 Barcelona, Spain.
14	2.	Biomedical Research Networking Center for Epidemiology and Public Health
15		(CIBERESP). Avenida Monforte de Lemos 3-5, 28029 Madrid, Spain.
16	3	Centre d'Atenció Primaria El Clot Institut Català de la Salut (ICS) Carrer

- 3. Centre d'Atenció Primaria El Clot, Institut Català de la Salut (ICS). Carrer 16 Concilio de Trento 25, 08018 Barcelona, Spain. 17
- 4. Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB). Carrer 18 19 Casanova, 143, 08036 Barcelona, Spain
- 5. Centre d'Atenció Primaria Center Numància, Institut Català de la Salut (ICS). 20 Carrer Numància 23, 08029 Barcelona, Spain. 21
- 6. Infectious Diseases Department, Hospital Universitari Parc Taulí. Institut 22 d'Investigació i Innovació Parc Taulí. Universitat Autònoma de Barcelona. Parc 23 Taulí, 1, 08208 Sabadell-Barcelona, Spain. 24
- 7. Centre d'Atenció Primaria Sant Miguel, Institut Català de la Salut (ICS). Carrer 25 Francesc Macià i Llussà, 154, 08401 Granollers-Barcelona, Spain. 26
- 8. Centre d'Atenció Primaria Adrià 5A Marc Aureli, Institut Català de la Salut (ICS). 27 Carrer Vallmajor, 34, 08021 Barcelona, Spain. 28
- 9. Centre d'Atenció Primaria Casanova. Consorci d'Atenció Primària de Salut de 29 l'Eixample (CAPSBE) Casanova. Carrer Rosselló 161, 08036 Barcelona, Spain. 30
- 10. Centre d'Atenció Primaria Torelló, Institut Català de la Salut (ICS). Avenida 31 32
- Pompeu Fabra, 8, 08570 Torelló-Barcelona, Spain. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

22	11 Department of Infectious Tropical diseases and Microbiology IRCCS Sacro
27	Cuera Don Calabria Hospital. Via Samprahoni 5, 27024 Nagrar di Valpolicalla
54 25	Cuore Don Calabria Hospital. Via Semprebolii 5, 57024 Negrai ul Valponcena,
35	Italy.
36	12. Spanish National Research Council (IPBLN-CSIC). Avenida del Conocimiento
37	17, Parque Tecnologico de Ciencias de la Salud, 18016, Granada, Spain.
38	13. Biomedical <i>Research</i> Networking Center (CIBER) of Infectious Diseases, Carlos
39	III Health Institute (CIBERINFEC, ISCIII). Carrer Melchor Fernández Almagro,
40	3, 28029 Madrid, Spain.
41	14. Liver Unit, Hospital Clínic, University of Barcelona, August Pi i Sunyer
42	Biomedical Research Institute (IDIBAPS), Biomedical Research Networking
43	Center of Hepatic and Digestive Diseases (CIBEREHD). Carrer Villarroel, 170,
44	08036 Barcelona, Spain.
45	15. Department of Medicine Solna, Karolinska Institutet. Solnavägen 1, 17177 Solna-
46	Stockholm, Sweden.
47	16. Department of Infectious Diseases, Karolinska University Hospital. Solnavägen 1,
48	17177 Solna-Stockholm, Sweden.
49	
50	[#] Both authors contributed equally.
51	†Both authors contributed equally.
52	
53	Grants that funded the project:
54	This study was supported by two grants from Instituto de Salud Carlos III (ISCIII), through
55	the "Fondo de Investigación para la Salud (FIS)", PI17/02020 and PI20/00866.
56	ARM receives funding from the Strategic Research Program in Epidemiology at Karolinska
57	Institutet.
58	The research team was supported by CIBER-Consorcio Centro de Investigación Biomédica
59	en Red-(CB 2021).
60	MCL was supported by the Programa Estatal I+D+I, Spanish Ministry of Science and
61	Innovation and FEDER (PID2019-109090RB-I00/AEI/10.13039/501100011033).
62	Authors from IRCCS Sacro Cuore Don Calabria Hospital were supported by the Italian

Ministry of Health "Fondi Ricerca corrente-L2P4".

- 64 Part of the data from this study were presented in the European Conference of Clinical
- 65 Microbiology and Infectious Diseases in Copenhagen (April 2023).
- 66
- 67
- 68 Corresponding author
- 69 Ana Requena-Méndez
- 70 Karolinska Institutet, Department of Medicine Solna.
- 71 Barcelona Institute for Global Health
- 72 requena.mendez@ki.se
- 73 Tel: +46702010789
- 74
- 75
- 76
- 77
- ..
- 78
- 79
- 80
- 81

4

82 Abstract

Background: In this study we have evaluated the performance of a novel multiplex serological assay with a panel of 8 antigens able to simultaneously detect IgG to HIV, chronic hepatitis B (HBV) and C (HCV), Chagas disease, strongyloidiasis and schistosomiasis as a screening tool for imported diseases in migrants.

Methods: Six panels of 40 well-characterized, anonymized serum samples from individuals with the respective confirmed infections (n=240) were used as positive controls to assess the sensitivity of the multiplex assay. One panel of 40 sera from non-infected subjects were used to estimate the seropositivity cutoffs for each infection, and 32 additional non-infected sera were used as negative controls to estimate the sensitivity and specificity for each serology. The multi-infection screening test was validated in a prospective cohort of 48 migrants from endemic areas to assess assay performance.

94 The sensitivity of the Luminex assay was calculated as the proportion of positive test results 95 over all positive samples by the primary reference test. The specificity was calculated using 96 32 negative samples. Uncertainty was quantified with 95% confidence intervals (CI) using 97 receiver operating characteristic analyses.

Results: The sensitivity /specificity were 100%/100% for HIV (p41 antigen), 97.5%/100%
(AUC:0.99,[95%CI: 0.96-1.00]) for HBV (core antigen), 100%/100% (AUC:1.00,[95%CI
1.00-1.00]) for HCV (core antigen), 92.5%/90.6%,(AUC:0.96,[95%CI 0.91-1.00]) for
strongyloidiasis (31-kDa recombinant antigen (NIE)), 97.5%/100%,(AUC:0.97,[95%CI 0.931]) for schistosomiasis (combined serpin *Schistosoma mansoni* and *S.haematobium* antigens)
and 92.5%/96.9%,(AUC: 0.96,[95%CI 0.92-1.00]) for Chagas disease ([*T.cruzi* kinetoplastid
membrane protein-11 (KMP11)]).

In the migrant cohort, antibody response to KMP11 correctly identified 14/14(100%)
individuals with Chagas disease, whereas HBV-core antigen and NIE-Strongyloides correctly
identified 91.7% and 86.4% individuals with chronic hepatitis B and strongyloidiasis
respectively.

109 Conclusions: We have developed a new 8-plex Luminex assay that is robust and accurate,
110 and could facilitate the implementation of screening programmes for imported diseases in
111 migrant populations.

- 113 Key words: Migrants, Hepatitis C virus, Hepatitis B virus, Strongyloides, Schistosomiasis,
- 114 Chagas disease, Luminex, IgG, sensitivity, specificity, screening, imported diseases, travel-
- 115 related illnesses.

6

117 INTRODUCTION

Migration is a complex and growing global phenomenon, of critical importance to European, 118 North American and other countries such as Australia and New Zealand (Western countries). 119 Most migrants are disproportionately affected by certain infections such as tuberculosis, 120 human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV), 121 and multiple studies have reported higher prevalence of such infections among them 122 compared with autochthonous populations.^{1,2} In 2020, 44% of new HIV diagnoses were 123 attributed to migrants living in the European Union, particularly migrants from sub-Saharan 124 Africa.³ Similarly, migrants from certain regions are at increased risk of hepatitis B and C 125 whereas for other regions, the risk is even lower compared to the autochthonous population.² 126

Other parasitic infections, such as Chagas disease, strongyloidiasis and schistosomiasis, 127 which are not endemic in Western countries, -with the exception of strongyloidiasis in few 128 areas-, are highly prevalent among migrants⁴⁻⁶. Chagas disease, caused by *Trypanosoma cruzi* 129 is a public health concern due to the high pooled prevalence (4.2%) among migrants from 130 Latin-American endemic countries living in Europe⁵, which is particularly high in Bolivian 131 migrants $(18\%)^7$; but also due to the possibility of autochthonous transmission (congenitally, 132 by transfusion, or transplantation,⁸) with a subsequent increase of related morbidity in 133 national health systems from Western countries, particularly in immunosuppressed patients 134 due to the risk of reactivation.⁹ Strongyloidiasis is also an emerging infection which is of 135 public health concern due to the possibility of being a life-threatening pathology when 136 immunosuppression is established.¹⁰ Schistosomiasis is a neglected tropical disease becoming 137 relevant in low- and non-endemic countries because of the increased migration flows from 138 high-endemic countries. It represents a management challenge due to the lack of clinical 139 awareness and knowledge among health professionals.¹¹ 140

Early detection and treatment of these infections can lower the related morbidity and mortality.¹¹ The European Centre for Disease Prevention and Control (ECDC) guidance on screening of infections in migrants,¹² recommends the screening of HIV, HBV, HCV, strongyloidiasis and schistosomiasis. Chagas disease was not included in the ECDC screening and vaccination recommendations document, yet this disease has an impact in Europe's health system and some studies have demonstrated the cost-effectiveness of the strategy of screening migrants from endemic countries at primary care.⁸

7

The feasibility of innovative integrated screening programmes of infectious diseases, has
been proven in different settings including primary care units in United Kingdom, United
States, Canada and Spain.^{11,13-15}

Antibody-based assays are used for assessing the exposure to different infections among 151 migrants including HIV or viral hepatitis,¹⁶ and also parasites (*Strongyloides stercoralis*¹⁷, 152 Schistosoma spp¹⁸ and T. $cruzi^{19}$) for which methods aiming at the direct detection of the 153 parasites or their DNA have lower sensitivity. Quantitative suspension array assays 154 simultaneously detecting antibodies to multiple pathogens using a single specimen can 155 support a more cost-effective implementation of integrated disease surveillance systems. In 156 addition, rapid tests with single but also with multiple biomarkers are gaining popularity in 157 low-income countries. In this regard, the dual rapid HIV and Treponema pallidum diagnostic 158 test is an example of multiple-test that has been utilized in integrated screening systems. 159

Luminex technology is gaining traction in diagnosis because of the ease, high throughput, and minimal sample volume requirements. It has been used to perform the surveillance of tropical viral infections,²⁰ enteropathogens,²¹ or malaria.²² More recently another new multiplex-test has been developed to detect HIV, viral hepatitis, herpes and *T. pallidum*.²³

Our study aimed to develop a new multiplex serological assay using 10 antigens to quantify IgG to six pathogens that are prevalent in migrant populations living in Catalonia (Spain), including HIV, HBV, HCV, *T. cruzi, S. stercoralis* and *Schistosoma* spp., and to estimate its sensitivity and specificity compared with primary reference standard tests for each infection.

168

169 METHODS

170 Study design

The study was performed using six panels of archived, fully anonymized well-characterized
coded serum samples previously diagnosed for the different infections, plus a group of
samples from non-infected subjects.

Each panel consisted of 40 positive control specimens for each pathogen (HIV, HBV, HCV, *T. cruzi*, *Strongyloides* and *Schistosoma*). HIV positive controls were determined with the
Determine HIV-1/2 Rapid Test (Abbott Laboratories) and confirmed with the Unigold rapid
test (Trinity Biotech). HBV and HCV positive controls were determined by RNA quantitative
testing that measures the viral load. The schistosomiasis positive controls were positive for

8

179 stool and/or urine test depending on the species. The strongyloidiasis positive controls were individuals diagnosed with strongyloidiasis and included in a clinical trial that assessed the 180 effectiveness of ivermectin²⁴ and for which the inclusion criteria were having a positive 181 faecal test for S. stercoralis or having a positive serological test at high titers irrespective of 182 the result of faecal test. High titers were assessed as at least 160 titer for the indirect 183 fluorescent antibody test (IFAT)- that is, whole serum dilution 1/160, and at least 2x 184 normalized optical density(OD) for the IVD Research ELISA, -that it, the ration between OD 185 of the sample and that of the weak positive control-²⁵. The accuracy of these tests at these 186 high titers have been validated showing that they approach 100% specificity, while 187 maintaining 70% sensitivity.²⁵ The *T. cruzi* positive controls were obtained from a serum 188 biobank of Chagas cases defined by being positive in at least two serological tests using 189 different recombinant antigens. For the parasitic infections, further details of the serological 190 titers, and faecal or urine samples in case of strongyloidiasis and schistosomiasis are reported 191 in Annex 1. From the panel of 72 sera of healthy subjects, 40 samples were used to estimate 192 the seropositivity cutoffs for the different serologies, and 32 were used as negative controls to 193 estimate the specificity for each serology. We validated the multi-infection screening test in a 194 prospective cohort of 48 migrants with epidemiological exposure risk to the above infections 195 196 depending on the country of origin. They were recruited during the implementation of a multi-disease screening program for asymptomatic migrants attended at primary care units in 197 198 Catalonia, (January 2019 - December 2020). They were tested for each infection with the reference method depending on the exposure risk. 199

200 The reference serological tests used to assess the accuracy of the Luminex in the prospective 201 migrant cohort were performed according to each centre's referral laboratory for HIV and viral hepatitis; for *Strongyloides*, an enzyme-linked immuno-sorbent assay (ELISA) based on 202 crude antigen 203 IVD-S.stercoralis (SCIMEDX, Dover-NJ,) or in-house an immunofluorescence; for Schistosoma, an ELISA or an in-house indirect-haemagglutination 204 test (Schistosomiasis-Fumouze, Levallois-Perret,); for T. cruzi, a commercial ELISA with 205 recombinant antigens (BioELISA-Chagas, Biokit-SA), and an in-house ELISA with whole 206 epimastigotes antigen²⁶, with diagnosis defined by positivity in both serological tests. 207

208 Multi-infection IgG Luminex assay.

The 10 antigens initially selected for the study are listed in Table 1. P24 (core antigen) and gp41 (envelope antigen) were selected for HIV serology, the first one for being indicative of acute infection²⁷ and the second one for being highly immunogenic during seroconversion²⁸

9

212 the 31-kDa recombinant antigen (NIE) antigen was selected for the serology of S. stercoralis, as ELISAs based on this antigen have shown high sensitivity in the range of 71-213 84%^{25,29,30} S.mansoni (Sm) and S.haematobium (Sh) serpins were selected for the serology of 214 the corresponding species for being reported as promising species-specific diagnostic 215 antigens by Luminex³¹, hepatitis C core and nonstructural protein 3 (NS3) antigens were 216 tested for chronic hepatitis C infection, the core antigen is currently used for diagnostic³² and 217 the NS3 antigen has also been reported as seroreactive³³, hepatitis B core (anti-HBc) antigen 218 was used for the detection of chronic hepatitis B infection as the presence of IgG indicates 219 ongoing infection, and people who have immunity to hepatitis B from a vaccine do not 220 develop anti-HBc³⁴. Finally, paraflagellar rod proteins 2 (PFR2)1 and T.cruzi kinetoplastid 221 membrane protein-11 (KMP11) antigens were selected for being previously reported as good 222 markers of *T.cruzi* infection^{35.} 223

Each of the 10 antigens included in the Luminex panel was coupled to a specific magnetic microsphere region; the optimal bead-coupling concentration was determined for each using the same methodology, as described previously.³⁶

227 A detailed description of the assays is provided in Annex 2. Briefly, 361 samples were tested together with serial dilutions of a positive control to generate a standard curve for assay 228 229 quality control, plus 3 technical blanks. Antigen-coupled microspheres were added in multiplex to the 384-well plate (2000 beads/ antigen/ well) and mixed with test samples, 230 positive controls, and blanks. Final dilution of test samples was 1/250. The plate was 231 incubated for 1 h at room temperature in agitation and protected from light. Then, the plate 232 was washed and 25µL of goat anti-human IgG-phycoerythrin,(1:400) were added to each well 233 and incubated for 30 min. The plate was washed again and microspheres resuspended with 234 Luminex Buffer, to be acquired on the Flexmap-3D® reader. At least 50 235 microspheres/analyte/well were acquired, and median fluorescence intensity (MFI) was 236 reported. Annex 3 shows the standard curves made of 20 serial dilutions of the positive 237 control. Reference standard results were blinded to the researchers who performed the 238 239 Luminex test.

240 Data analysis

MFI cutoffs for seropositivity were calculated for each antigen as the exponential function of the mean plus 2 standard deviations (SD) or 3SD of log₁₀-transformed MFIs of 40 negative controls randomly selected among the specimens from 72 subjects with no previous exposure

10

to any infection. The other 32 negative controls were used to estimate the specificity of the 244 Luminex assay vs the reference tests. Thereafter, for each infection, the evaluation of the 245 Luminex assay performance used 72 specimens with known serological status (40 positive 246 and 32 negative samples). The sensitivity of the Luminex test was calculated as the 247 proportion of positive results (based on the cut-off with 2SD) over all positive samples by the 248 primary reference test. Sensitivity was also calculated with the cutoff with 3SD. Similarly, 249 specificity was calculated over 32 control negative samples from the group of healthy 250 controls using both 2SD and 3SD cutoffs. Uncertainty was quantified with 95% confidence 251 252 intervals (CI) using receiver operating characteristic (ROC) analyses. Finally, the sensitivity and specificity were also estimated in a panel of samples prospectively collected from 48 253 migrants at risk of infections. 254

255 Ethics

Positive and negative control samples used to develop the assay were obtained from collections registered at the Instituto de Salud Carlos III, Hospital Clínic(Barcelona)/ISGlobal biobanks and Sacro-Cuore Hospital Tropica-Biobank (Annex 4). The study protocol and informed consent from migrants whose samples were prospectively collected were approved by the ethical committee at Hospital Clínic, (HCB/2017/0847). Results are reported according to the STARD-checklist (Annex 5).

262

263 **RESULTS**

264 Accuracy of the multi-infection Luminex assay on a reference panel of human samples

We evaluated the performance of the novel multiplex serological assay on a panel of human sera with known infection status. First, we estimated the seropositivity cutoffs for each of the antigens in the Luminex panel using 2 and 3SD, summarized in Annex 6.

Figure 1 represents the IgG serological levels ($log_{10}MFI$) against each antigen in the Luminex panel in 32 negative and 246 positive control samples (1A), and 48 test samples from migrants exposed to the infections (1B).

Using a 2SD cutoff, the sensitivity was generally high (>90%) for the majority of the antigens, whereas the specificity depended on the pathogen and antigen (Table 2 and Figure 2). The sensitivity and specificity of the Luminex test for detecting HIV using the gp41 recombinant protein determined by ROC analysis were 100% using both 2SD and 3SD

cutoffs. In contrast, the p24 protein performed worse, with a sensitivity of 87.5% and a
specificity of 96.9% with the 2SD cutoff, and 80% sensitivity at 3SD cutoff (Figure 2A).

The HBV core antigen showed a sensitivity of 97.5% at 2SD-cutoff and 95% at 3SD-cutoff, and a specificity of 100% (2SD and 3SD-cutoff), (AUC: 0.99, [95%CI: 0.96-1.00]), (Figure 2B). The HCV core antigen showed a 100% sensitivity at 2SD-cutoff (97.5% at 3SD-cutoff) and a specificity of 100% (2SD and 3SD-cutoff),(AUC: 1.00,[95%CI 1.00-1.00]), (Figure 2C).

Strongyloides-NIE antigen reported a sensitivity of 92.5% (2SD and 3SD-cutoff) and specificities of 90.6% (2SD-cuttoff) and 100% (3SD-cutoffs), (AUC:0.96, [95%CI 0.91-1.00]), (Figure 2D). In a restricted analysis (Annex 7) to those samples that tested positive in feces [(either by polymerase chain reaction (PCR) test or any other direct technique]), the performance of the NIE antigen in Luminex with the 3SD cutoff improved to 100% sensitivity (AUC: 1.00, [95%CI 1.00-1.00]).

- The sensitivity and specificity of the Luminex test to detect schistosomiasis was 97.5% and 93.8% (2SD cutoff),(AUC:0.97, [95%CI 0.93-1.00]) using *S. haematobium* (Sh) *and S. mansoni* (Sm) serpin antigens together, (Figure 2E). Interestingly, the sensitivity of the serpin-Sh antigen was 100% for detecting *S. haematobium* infections whereas the sensitivity of the serpin-Sm antigen was 96% for detecting *S. mansoni* infections (Annex 7).
- The *T. cruzi* KMP11 antigen performed better (Sen 92.5%, Spec 96.9%, AUC:0.96, [95%CI 0.92-1.00]) compared to the PFR2 antigen (Sen 77.5%; Spec 93.8, AUC:0.87, [95%CI 0.80-0.94]). Furthermore, when combining both antigens, the sensitivity increased to 95% (AUC:0.97, [95%CI 0.93-1.00]) (Figure 2F). There were two samples in the *T. cruzi* infection panel that resulted indeterminate by the reference test, and it was necessary a third serological test to confirm the infection. After excluding these samples from the analysis (Annex 7), the sensitivity increased to 97.4% at 2SD cutoff (AUC:0.98, [95%CI 09.95-1.00]).
- In order to assess possible cross-reactivities, we evaluated for each infection the false positive rate among the individuals from the six panels of positive controls (Annex 8). Overall, the Luminex serology showed a low frequency of false positives, except for *S. stercoralis* showing a rate of 66% (12/18) and 50% (9/18) among *Schistosoma* spp. Infections at a cutoff of 2SD and 3SD respectively, and 62% (13/21) and 38% (8/21) in *Schistosoma* spp. and HBV coinfections at a cutoff of 2SD and 3SD respectively. There were 25% (5/20) false positives

12

for HIV and 36% (4/11) for HCV in *Schistosoma* spp. and HBV coinfections at a cutoff of

307 2SD that were not observed at 3SD.

308 Accuracy of the multi-infection Luminex assay on migrant's cohort

There were no positive reference tests for HIV, HCV, and schistosomiasis among the migrant's cohort, therefore the sensitivity and AUC of the Luminex test for these infections could not be evaluated. The specificities assessed for each of these infections are detailed in table 3.

- Among the 48 individuals tested for HBV, 11 of them had a positive anti-HBc test result. The core HBV antigen tested in Luminex showed a sensitivity of 100% and specificity of 89.2% (2SD-cutoff). For the KMP11- Chagas antigen, the Luminex assay correctly identified (2SD and 3SD-cutoffs) the 14 positive and 16 negative cases detected with the reference method (100% Sens and 100% Spec, AUC: 1.00, [95%CI 1.00-1.00]). The NIE-antigen showed 83.3% sensitivity and 86.8% specificity, at 2SD-cutoff.
- We also assessed for cross-reactivities among the 48 individuals from the migrant's cohort (Annex 9), and frequency of false positives was overall low, except for *S. stercoralis infections* with 20% (2/10) false positives among *T. cruzi* but only at 2SD and 28% (2/7) among HBV infections at 2SD and 15% (1/7) at 3SD cutoff. HIV showed 32% (4/12) false positives among the *T. cruzi* infected individuals at 2SD (only 1 at 3 SD), and *Schistosoma* spp. showed 28% (2/7) among HBV infected individuals, using the 2SD and 2 SD cutoff.
- 325

326 **DISCUSSION**

We have developed a 8-plex Luminex assay for the simultaneous detection of IgG against HIV, HBV, HCV, *Schistosoma* spp, *S. stercoralis* and *T. cruzi*. To our knowledge, this is the first multiplex test that simultaneously detects several viral and parasitic infections based on serological tests that are prevalent in migrant populations. Although 10 antigens were initially evaluated, only 8 of them showed a good performance.

Our 8-plex assay results showed a good agreement with the reference tests, being highly accurate to detect most pathogens, particularly gp41-HIV and HCV-core antigen, (100% sensitivity), the combination of *Schistosoma* serpin antigens (97.5%), HBV core antigen (97.5%) and the combination of *T. cruzi* antigens (95%).

13

336 For the infections for which two antigens were tested, the sensitivity of the test increased for Chagas disease and schistosomiasis, whereas for HIV the combination of p24 and gp41 337 antigens slightly decreased the specificity of the test compared with the use of the gp41 338 antigen alone. P24 antigen tends to negativize over time after the infection³⁷, as it is only 339 detected in blood during early stages of the primoinfection, thus it is not reliable for screening 340 except for the detection of recent infections.³⁸ Similarly to other studies,³⁹ for HCV the 341 combination of NS3 with the core antigen decreased the specificity of the test compared with 342 the core antigen alone. The performance of HIV and HBV antigens was similar compared 343 with a previous Luminex study, whereas the core HCV antigen has demonstrated better 344 performance.²³ However HIV gp41 and HCV-core antigens showed some false positives in 345 Schistosoma spp. and HBV coinfections, and HIV also in *T.cruzi* infections, suggesting some 346 room for improvement. 347

As previously described, the performance of the recombinant Strongyloides-NIE antigen 348 (sensitivity 92.5%) is not as good as other commercially available tests based on crude 349 antigens.²⁵ However, the sensitivity was 100% for those infections detected by microscopy or 350 PCR. Therefore, the lower sensitivity of NIE by Luminex can be attributed to a poorer 351 diagnostic capability of the recombinant antigen compared with crude antigens.⁷ However, 352 the *Strongyloides* serology with crude antigen may give false positives due to cross-reactivity 353 354 with other helminths, such as, filarial infections, Ascaris lumbricoides infection, and acute schistosome infections⁴⁰, thus these specimens could also be true negatives wrongly 355 356 characterized by the reference test. In fact, when assessing the rate of false positives due to possible cross reactivities, S. stercoralis showed a high prevalence of false positives among 357 other infections suggesting the need to improve the specificity for the NIE antigen. 358

Concerning Chagas disease, although the combination of both antigens showed a better sensitivity, the KMP11 antigen performed much better compared with PFR2 antigen to detect T. cruzi, improving even the accuracy when excluding borderline results detected by the reference test, which suggests that this antigen is performing similar compared with other serological tests developed for T. cruzi screening.⁴¹ In any case, the diagnosis of Chagas disease by Luminex should be confirmed with another serological test using a different recombinant protein, as standard procedure.

Interestingly, when the Luminex assay was tested in a prospective sample of migrant individuals coming from countries endemic for the infections tested, the assay showed a good accuracy to detect most infections, although sensitivity was lower for strongyloidiasis,

14

369 suggesting that this Luminex panel may be promising as a screening tool. However, the 370 migrants sample size was very small and there were no patients with patients with 371 schistosomiasis, HIV, and hepatitis C.

We have tested the performance of the 10 antigens using two different cutoffs. The 2SDcutoff gives higher sensitivities by losing some specificity, while the 3SD-cutoff gives lower sensitivities but 100% specificity for all infections. In the context of screening of migrant populations, higher sensitivities are more important than 100% specificities, as having infected undiagnosed individuals is not desirable, therefore false negative cases should be minimized.

Overall, the use of bead-based multiplex assays is gaining recognition in diagnosis of 378 infections because of the ease, high throughput, and minimal sample/reagent volume 379 requirements⁴²⁻⁴⁴ allowing measuring up to 100 analytes/per sample, and the FlexMap-3D 380 platform (the one used in this study) up to 500 analytes per sample, with comprehensive 381 reductions in time and cost. Remarkably, multiplexing more than one antigen may increase 382 the sensitivity of pathogen detection compared to single-biomarkers. In addition, Luminex 383 panels are flexible and can be adapted to the epidemiological risk of individuals (i.e., the 384 country of origin). Thus, for example T cruzi antigen could be only included in a specific 385 386 Luminex panel for Latin American migrants.

In this specific study, we evaluated the diagnostic utility of a multiplex test focusing on the positivity or negativity of samples, however antibody levels could be useful in studies addressing IgG kinetics since time of infection, or IgG levels depending on viral or parasitic loads.

Although the Luminex technology itself is not novel, to our knowledge, this is the first 391 392 multiplex test that simultaneously detects several viral and parasitic infections that are prevalent in migrant populations based on serological tests. The simultaneous classification 393 394 for the presence or absence of multiple pathogens in a single assay has the potential to revolutionize and simplify the public health and diseases surveillance in endemic areas where 395 the infections are prevalent,⁴⁴ and also the implementation of screening programmes in 396 migrant populations. Moreover, 5 of the 10 proteins used in the panel are not commercially 397 available thus have been produced in house, and for some of them this is the first time that 398 their diagnostic performance is reported as part of a multi-diagnostic infection test. 399

In addition, the 8-plex assay overcomes many of the laboratory infrastructure requirements of
 the single infection diagnostic testing, thereby simplifying the logistics. This makes it a more
 accessible test for settings that may not have either the technical knowledge or the

15

infrastructure capacity to conduct the single diagnostic tests using a dedicated platform for
each of them (i.e., primary care). In this regard, the current existence of benchtop compact
easy-to-use multiplex equipment, would facilitate the development of a point of care version
of the assay in primary care.

While further work is needed to optimize and validate this 8-plex assay, and maybe expand it to other infections, and to other assays using non-invasive samples such as mucosa or saliva, it has the potential to drastically reduce the disease burden in settings where testing has often been limited, particularly for imported parasitic diseases.

A detailed comparative cost-analysis between the multiplex assay and the individual standard
conventional tests for each infection is in progress, this test has substantial potential to
improve diagnostic testing, based on this proof-of-concept study.

414 The main limitation of the study is the small sample size of the prospective sample with no

diagnosed cases for some of the infections. For this reason, we plan to conduct a more robust

416 prospective study for the validation of the 8-plex assay. Another limitation of the study is the

417 lack of a proper challenge panel made up of samples from infections and conditions that may

418 cause potential cross-reactivity (i.e., filariasis in the case of strongyloidiasis)⁷. The reason

419 was the lack of samples with known unique infections for this purpose. Instead, we have used

420 the data from the individuals from the six panels of positive controls and the 48 tested

421 individuals with information on other infections as challenge panels. We are measuring IgG,

422 which is indicative of exposure, not distinguishing between current or past infection.

423 However, the Luminex platform allows measuring any isotype or IgG subclass, thus IgM or

424 IgA could be used in combination with IgG to distinguish recent from past infections. In

425 addition, the use of specific antigens can be helpful to determine the approximate time of

426 infection.

427

428 **Conclusions**

We present a proof-of-principle of the excellent performance of a high through put single test using multiplexed antigens with a minimal sample volume that can detect multiple infections, common in migrant populations. Our 8-plex assay has shown to be robust and accurate, although further prospective study should validate the reproducibility of the assay. This test could facilitate the implementation of screening programmes particularly in non-hospitalbased settings where the detection of single pathogens can be logistically challenging and expensive.

16

436

437 Acknowledgements

We are grateful to all patients who participated in this study, the general practitioners, nurses, 438 and other staff from the primary care centres and hospitals who were committed to perform 439 the field work required for the study while maintaining their daily tasks. Specially, we 440 acknowledge the work carried by Maria Luisa Machado and Silvia Capilla from Hospital 441 Universitari Parc Taulí. Special thanks to the research group at the IRCCS Sacro Cuore Don 442 Calabria Hospital for providing the positive control samples for strongyloidiasis (part of 443 them) and schistosomiasis, in particular to Stefano Tais and Monica Degani, to Jose Munoz 444 445 (Hospital Clinic, Barcelona) for facilitating positive control samples for strongyloidiasis (part of them) and Denise Naniche (ISGlobal) for information on the HIV positive control samples. 446 We are also grateful to M^a Carmen Thomas from the Institute of Parasitology 447 and Biomedicine López Neyra for supplying the Chagas disease antigens, Thomas 448 449 Nutman (NIH/NIAID,USA), Sukwan Handali (CDC) for supplying the NIE, Satoshi Kaneko (Nagasaki University, Japan) for donating the Sm and Sh serpins, and Marta 450 451 Vidal, Rebeca Santano and Inocencia Cuamba for support in the antigen procurement and characterization. 452

453 **Funding**

This study was supported by two grants from Instituto de Salud Carlos III (ISCIII), co-454 financed by the European Regional Development Fund (FEDER) from the European Union, 455 456 through the "Fondo de Investigación para la Salud (FIS)", PI17/02020 and PI20/00866. ARM receives funding from the Strategic Research Program in Epidemiology at Karolinska 457 458 Institutet. This research team was supported by CIBER-Consorcio Centro de Investigación Biomédica en Red-(CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e 459 460 Innovación and Unión Europea. MCL was supported by the Programa Estatal I+D+I, Spanish FEDER Ministry of Science and Innovation and (PID2019-109090RB-461 I00/AEI/10.13039/501100011033). Authors from IRCCS Sacro Cuore Don Calabria Hospital 462 were supported by the Italian Ministry of Health "Fondi Ricerca corrente-L2P4". ISGlobal 463 464 receives support from the Spanish Ministry of Science and Innovation through the "Centro de Excelencia Severo Ochoa 2019-2023" Program (CEX2018-000806-S), and support from the 465 Generalitat de Catalunya through the CERCA Program. 466

467 The funders of the study had no role in the study design, data collection, data analysis, data468 interpretation or writing of the manuscript.

469 Author contribution

- 470 Study design by ARM, RA, AJ and CD. Field work done by CRS, MGL, OGB, GF, AJL,
- 471 AMP, RSC. Sample processing carried out by AJ, RA and CD. Methodology developed by
- 472 RA, AC and ARM. Interpretation of results executed by AC, ARM and AJ. The manuscript
- 473 has been drafted by RA, AC, AJ, CD and ARM. All authors have contributed to the writing,
- 474 reviewing and editing of the publication.

476 **REFERENCES**

477 1 European Centre for Disease Prevention and Control. Assessing the burden of key
478 infectious diseases affecting migrant populations in the EU/EEA. Stockholm, 2014
479 DOI:10.2900/28792.

Lazarus J V., Bromberg DJ, del Amo J, et al. Hepatitis C prevalence among the
migrant population in Spain: A systematic review and meta-analysis. Enferm Infecc
Microbiol Clin 2019; 37: 222–30.

483 3 European Centre for Disease Prevention and Control, WHO Regional Office for
484 Europe. HIV/AIDS surveillance in Europe 2021 - 2020 data. Stockholm: ECDC, 2021.

485 4 Asundi A, Beliavsky A, Liu XJ, et al. Prevalence of strongyloidiasis and
486 schistosomiasis among migrants: a systematic review and meta-analysis. Lancet Glob Health
487 2019; 7: e236–48.

488 5 Requena-Méndez A, Aldasoro E, de Lazzari E, et al. Prevalence of Chagas disease in
489 Latin-American migrants living in Europe: a systematic review and meta-analysis. PLoS
490 Negl Trop Dis 2015; 9: e0003540.

491 6 Navarro M, Reguero L, Subir C, Bl A, Requena-m A. Estimating chagas disease
492 prevalence and number of underdiagnosed, and undertreated individuals in Spain. 2022 May493 June; 47:102284. DOI:10.1016/j.tmaid.2022.102284.

494 7 1 European Centre for Disease Prevention and Control. Assessing the burden of
495 key infectious diseases affecting migrant populations in the EU/EEA. Stockholm, 2014
496 DOI:10.2900/28792.

497 2 Lazarus J V., Bromberg DJ, del Amo J, et al. Hepatitis C prevalence among the
498 migrant population inSpain: A systematic review and meta-analysis. Enferm Infecc Microbiol
499 Clin 2019; 37: 222–30.

European Centre for Disease Prevention and Control, WHO Regional Office for
 Europe. HIV/AIDS surveillance in Europe 2021 - 2020 data. Stockholm: ECDC, 2021.

Asundi A, Beliavsky A, Liu XJ, et al. Prevalence of strongyloidiasis and
schistosomiasis among migrants: a systematic review and meta-analysis. Lancet Glob Health
2019; 7: e236–48.

505 5 Requena-Méndez A, Aldasoro E, de Lazzari E, et al. Prevalence of Chagas disease in
506 Latin-American migrants living in Europe: a systematic review and meta-analysis. PLoS
507 Negl Trop Dis 2015; 9: e0003540.

Navarro M, Reguero L, Subir C, Bl A, Requena-m A. Estimating chagas disease
prevalence and number of underdiagnosed, and undertreated individuals in Spain. 2022; 47.
DOI:10.1016/j.tmaid.2022.102284.

511 7 Requena-Mendez A, Buonfrate D, Bisoffi Z, Gutiérrez JM. Advances in the
512 Diagnosis of Human Strongyloidiasis. Curr Trop Med Rep 2014; 1: 207–15.

19

8 Requena-Méndez A, Bussion S, Aldasoro E, et al. Cost-effectiveness of Chagas
disease screening in Latin American migrants at primary health-care centres in Europe: a
Markov model analysis. Lancet Glob Health 2017; 5: e439–47.

Requena-Méndez A, Albajar-Viñas P, Angheben A, Chiodini P, Gascón J, Muñoz J.
Health Policies to Control Chagas Disease Transmission in European Countries. PLoS Negl
Trop Dis 2014 Oct 30; 8(10):e3245. DOI:10.1371/journal.pntd.0003245.

519 10 Buonfrate D, Requena-Mendez A, Angheben A, et al. Severe strongyloidiasis: a
520 systematic review of case reports. BMC Infect Dis 2013 Feb 8; 13: 78.

521 11 Sequeira-Aymar E, Cruz A, Serra-Burriel M, et al. Improving the detection of
522 infectious diseases in at-risk migrants with an innovative integrated multi-infection screening
523 digital decision support tool (IS-MiHealth) in primary care: A pilot cluster-randomized
524 controlled trial. J Travel Med 2022 Nov 4; 29(7):taab100.

ECDC. Public health guidance on screening and vaccination for infectious diseases in
newly arrived migrants within the EU/EEA. 2018.

527 13 Eborall H, Wobi F, Ellis K, et al. Integrated screening of migrants for multiple
528 infectious diseases: Qualitative study of a city-wide programme. EClinicalMedicine 2020
529 Apr 18; 21:100315.

María JM, Vivancos J, Lidia CG, et al. Hepatitis C and HIV combined screening in
primary care : A cluster randomized trial. J Viral Hepat. 2021 Feb;28(2):345-352.

15 Redditt VJ, Graziano D. Health status of newly arrived refugees in Toronto , Ont. Can
Fam Physician. 2015 Jul; 61(7): e303–e309

534 16 Zangiabadian M, Zamani A, Nasiri MJ, Behzadi E, Fooladi AAI. Diagnostic
535 Accuracy and Validity of Serological and Molecular Tests for Hepatitis B and C. Curr Pharm
536 Biotechnol 2022; 23: 803–17.

17 Requena-Mendez A, Chiodini P, Bisoffi Z, et al. The laboratory diagnosis and follow
up of strongyloidiasis: a systematic review. PLoS Negl Trop Dis 2013; 7: e2002.

Agbata EN, Morton RL, Bisoffi Z, et al. Effectiveness of Screening and Treatment
Approaches for Schistosomiasis and Strongyloidiasis in Newly-Arrived Migrants from
Endemic Countries in the EU/EEA: A Systematic Review. Int J Environ Res Public Health.
2018 Dec 20;16(1):11. DOI:10.3390/ijerph16010011.

543 19 Abras A, Gállego M, Llovet T, et al. Serological Diagnosis of Chronic Chagas
544 Disease: Is It Time for a Change? J Clin Microbiol 2016; 54: 1566–72.

Raulino R, Thaurignac G, Butel C, et al. Multiplex detection of antibodies to
Chikungunya, O'nyong-nyong, Zika, Dengue, West Nile and Usutu viruses in diverse nonhuman primate species from Cameroon and the Democratic Republic of Congo. PLoS Negl
Trop Dis 2021; 15: 1–20.

Williams C, Cumming O, Grignard L, et al. Prevalence and diversity of enteric
pathogens among cholera treatment centre patients with acute diarrhea in Uvira, Democratic
Republic of Congo. BMC Infect Dis 2020 Oct;20(1):741. DOI:10.1186/S12879-020-05454-0.

20

Tetteh KKA, Wu L, Hall T, et al. Optimisation and standardisation of a multiplex
immunoassay of diverse Plasmodium falciparum antigens to assess changes in malaria
transmission using sero-epidemiology. Wellcome Open Res 2020 Apr 23;4:26.
DOI:10.12688/WELLCOMEOPENRES.14950.2.

Yufenyuy EL, Vedapuri S, Zheng A, et al. Development of a Bead-Based Multiplex
Assay for Use in Multianalyte Screening and Surveillance of HIV, Viral Hepatitis, Syphilis,
and Herpes. J Clin Microbiol 2022 May 18;60(5):e0234821. DOI:10.1128/JCM.02348-21.

559 24 Buonfrate D, Salas-Coronas J, Muñoz J, et al. Multiple-dose versus single-dose 560 ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-561 label, phase 3, randomised controlled superiority trial. Lancet Infect Dis 2019; 19: 1181–90.

562 25 Bisoffi Z, Buonfrate D, Sequi M, et al. Diagnostic Accuracy of Five Serologic Tests
563 for Strongyloides stercoralis Infection. PLoS Negl Trop Dis 2014; 8: e2640.

Riera C, Vergés M, López-Chejade P, et al. Desarrollo y evaluación de una técnica
ELISA con antígeno crudo de Trypanosoma cruzi para el diagnóstico de la Enfermedad de
Chagas. Enferm emerg 2009;11(1):22-29.

567 27 Saz J, Dalmau-Bueno A, Meulbroek M, et al. Use of fourth-generation rapid 568 combined antigen and antibody diagnostic tests for the detection of acute HIV infection in a 569 community centre for men who have sex with men, between 2016 and 2019. PLoS One 2021 570 Jul 27;16(7):e0255065. DOI:10.1371/JOURNAL.PONE.0255065.

571 28 Mayer-Blackwell K, Johnson AM, Potchen N, et al. Multi-trial analysis of HIV-1
572 envelope gp41-reactive antibodies among global recipients of candidate HIV-1 vaccines.
573 Front Immunol 2022 Oct 12;13:983313.

574 29 Krolewiecki AJ, Ramanathan R, Fink V, et al. Improved diagnosis of Strongyloides 575 stercoralis using recombinant antigen-based serologies in a community-wide study in 576 northern Argentina. Clinical and Vaccine Immunology 2010; 17: 1624–30.

577 30 Fradejas I, Herrero-Martínez JM, Lizasoaín M, Rodríguez De Las Parras E, Pérez578 Ayala A. Comparative study of two commercial tests for Strongyloides stercoralis serologic
579 diagnosis. Trans R Soc Trop Med Hyg 2018; 112: 561–7.

Tanigawa C, Fujii Y, Miura M, et al. Species-Specific Serological Detection for
Schistosomiasis by Serine Protease Inhibitor (SERPIN) in Multiplex Assay. PLoS Negl Trop
Dis 2015; 9: e0004021.

583 32 NICE: The National Institute for Health and Care excellence. Hepatitis B and C
584 testing: people at risk of infection. 2012. URL: <u>https://www.nice.org.uk/guidance/ph43</u>.
585 (Accessed June 8, 2023).

Marohnic CC, Birkenmeyer LG, Bogdan MF, et al. Engineering of the hepatitis C
virus helicase for enhanced seroreactivity. J Virol Methods 2019; 264: 11–7.

588 34 Interpretation of Hepatitis B Serologic Test Results | CDC.
589 https://www.cdc.gov/hepatitis/hbv/interpretationOfHepBSerologicResults.htm (accessed May
590 31, 2023).

591 35 Egui A, Carmen Thomas M, Fernández-Villegas A, et al. A Parasite Biomarker Set
592 for Evaluating Benznidazole Treatment Efficacy in Patients with Chronic Asymptomatic
593 Trypanosoma cruzi Infection. Antimicrob Agents Chemother 2019 Sep 23;63(10):e02436-18.
594 DOI:10.1128/AAC.02436-18/SUPPL_FILE/AAC.02436-18-S0001.PDF.

595 36 Ubillos I, Aguilar R, Sanz H, et al. Analysis of factors affecting the variability of a
596 quantitative suspension bead array assay measuring IgG to multiple Plasmodium antigens.
597 PLoS One 2018; 13: e0199278.

598 37 Viana IFT, Coêlho DF, Palma ML, et al. Detection of IgG3 antibodies specific to the 599 human immunodeficiency virus type 1 (HIV-1) p24 protein as marker for recently acquired 600 infection. Epidemiol Infect 2018; 146: 1293–300.

Brust S, Duttmann H, Gürtler L, Thortensson R, Simon F. Shortening of the
diagnostic window with a new combined HIV p24 antigen and anti-HIV-1/2/O screening test.
J Virol Methods 2000; 90: 153–65.

Gauna A, Losada S, Lorenzo M, et al. Use of Synthetic Peptides and Multiple Antigen
Blot Assay in the Immunodiagnosis of Hepatitis C Virus Infection. Viral Immunol 2018; 31:
568–74.

- Gam AA, Neva FA, Krotoski WA. Comparative sensitivity and specificity of ELISA
 and IHA for serodiagnosis of strongyloidiasis with larval antigens. Am J Trop Med Hyg
 1987; 37: 157–61.
- Kelly EA, Bulman CA, Gunderson EL, et al. Comparative Performance of LatestGeneration and FDA-Cleared Serology Tests for the Diagnosis of Chagas Disease. J Clin
 Microbiol 2021 May 19;59(6):e00158-21. DOI:10.1128/JCM.00158-21.
- 42 Arnold B, Scobie H, Priest J, Lammie P. Integrated serologic surveillance of
 population immunity and disease transmission. Emerg Infect Dis 2018; 24: 1188–94.
- 43 Priest J, Jenks M, Moss D, et al. Integration of multiplex bead assays for parasitic
 diseases into a national, population-based serosurvey of women 15-39 years of age in
 Cambodia. PLoS Negl Trop Dis 2016 May 3;10(5):e000469.
- Fujii Y, Kaneko S, Nzou S, et al. Serological surveillance development for tropical
 infectious diseases using simultaneous microsphere-based multiplex assays and finite mixture
 models. PLoS Negl Trop Dis 2014 Jul 31;8(7):e304.
- 45 McManus M, Karalius B, Patel K, Persaud D, Luzuriaga K. Quantitative HIV-1specific antibodies as predictors of peripheral blood cell-associated HIV-1 DNA
 concentrations. AIDS 2020; 34: 1117–26.
- 46 Santano R, Rubio R, Grau-Pujol B, et al. Evaluation of antibody serology to
 determine current helminth and Plasmodium falciparum infections in a co-endemic area in
 Southern Mozambique. PLoS Negl Trop Dis 2022 Jun 21;16(6):e0010138.

47 Tanigawa C, Fujii Y, Miura M, et al. Species-Specific Serological Detection for
Schistosomiasis by Serine Protease Inhibitor (SERPIN) in Multiplex Assay. PLoS Negl Trop
Dis 2015 Aug 20;9(8):e000402.

22

630 48 Sillanpää M, Melén K, Porkka P, et al. Hepatitis C virus core, NS3, NS4B and NS5A
631 are the major immunogenic proteins in humoral immunity in chronic HCV infection. Virol J
632 2009; 6: 1–12.

49 Lee JH, Kim HS. Current laboratory tests for diagnosis of hepatitis B virus infection.
634 Int J Clin Pract 2021; 75: e14812.

635 50 Caviglia GP, Olivero A, Ciancio A, et al. Analytical and clinical evaluation of a novel
636 assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV
637 infection. Diagn Microbiol Infect Dis 2020 Apr;96(4):114985.

Alonso-Padilla J, López MC, Esteva M, et al. Serological reactivity against T. cruzi derived antigens: Evaluation of their suitability for the assessment of response to treatment in
 chronic Chagas disease. Acta Trop 2021 Sep;221:105990.

- 641
- 642
- 643
- 644
- C 4 F
- 645
- 646
- 647
- 648

23

649 **TABLES**

Table 1. The 10 antigens tested used in the multi-infection Luminex assay

Antigen	Pathogen	Source	Coupling	Reference
			concentration	27
Recombinant HIV1 p24 protein	HIV	Abcam ab43037	30µg/mL	3/
Recombinant HIV1 gp41 protein	HIV	Abcam ab49068	250µg/mL	45
NIE	Strongyloides	Expressed in <i>E. coli</i> by Sukwan Handali (CDC) from a plasmid clone donated by Thomas Nutman (NIH/NIAID), USA	10µg/mL	46
Sm serpin	Schistosoma mansoni	Donated by Satoshi Kaneko (Nagasaki University, Japan)	30µg/mL	47
Sh serpin	Schistosoma haematobium	Donated by Satoshi Kaneko (Nagasaki University, Japan)	50µg/mL	47
Recombinant Hepatitis C Virus NS3 protein	HCV	Abcam ab49024	50µg/mL	48
Recombinant Hepatitis C Virus Core Antigen	HCV	Abcam ab49017	50µg/mL	48
Recombinant Hepatitis B Virus Core Antigen	HBV	Abcam ab49013	30µg/mL	49,50
Chagas PFR2	Trypanosoma cruzi	Recombinant protein produced by Carmen Thomas and Manuel C. Lopez, IPBLN-CSIC, Granada, Spain	50µg/mL	51
Chagas KMP11	Trypanosoma cruzi	Recombinant protein produced by Carmen Thomas and Manuel C. Lopez IPBLN-CSIC, Granada, Spain)	30µg/mL	51
HIV: Human Immunodefic haematobium; NS3: non-s	tiency Virus, HBV: Hep tructural protein 3; PFR	patitis B Virus, HCV: Hepatitis C Virus; Sm: Schistosoma ma 2: paraflagellar rod protein 2; KMP11: kinetoplastid membra	<i>unsoni</i> ; Sh: <i>Schi</i> stine protein-11	stosoma

		2 SD cutoff				3 SD cutoff					AUC	
	Antigens	Pos T / Pos GS	Sensitivity	Neg T / Neg GS	Specificity	Correctly classified	Pos T / Pos GS	Sensitivity	Neg T / Neg GS	Specificity	Correctly classified	
	p24	35/40	87.5	31/32	96.9	91.7	32/40	80.0	32/32	100	88.9	0.93 (0.88-0.99)
HIV	gp41	40/40	100	32/32	100	100	40/40	100	32/32	100	100	1.00 (1.00-1.00)
	Both	40/40	100	31/32	96.9	98.6	40/40	100	32/32	100	100	1.00 (1.00-1.00)
HBV	HBV core	39/40	97.5	32/32	100	98.6	38/40	95	32/32	100	97.2	0.99 (0.96-1.00)
	HCV core	40/40	100	32/32	100	100	39/40	97.5	32/32	100	98.6	1.00 (1.00-1.00)
HCV	HCV NS3	33/40	82.5	31/32	96.9	88.9	31/40	77.5	32/32	100	87.5	0.91 (0.85-0.97)
	Both	40/40	100	31/32	96.9	98.6	39/40	97.5	32/32	100	98.6	1.00 (1.00-1.00)
	PFR2	31/40	77.5	30/32	93.8	84.7	17/40	42.5	32/32	100	68.1	0.87 (0.80-0.94)
Chagas disease	KMP11	37/40	92.5	31/32	96.9	94.4	34/40	85.0	32/32	100	91.7	0.96 (0.92-1.00)
	Both	38/40	95.0	29/32	90.6	93.1	34/40	85.0	32/32	100	91.7	0.97 (0.93-1.00)
Strongyloides	NIE	37/40	92.5	29/32	90.6	91.7	37/40	92.5	32/32	100	95.8	0.96 (0.91-1.00)
	Sm - serpin	36/40	90.0	31/32	96.9	93.1	31/40	77.5	32/32	100	87.5	0.95 (0.90-1.00)
Schistosoma	Sh - serpin	36/40	90.0	31/32	96.9	93.1	29/40	72.5	31/32	96.9	83.3	0.92 (0.87-0.99)
spp	Both	39/40	97.5	30/32	93.8	95.8	36/40	90.0	31/32	96.9	93.1	0.97 (0.93-1.00)
Pos T: positive test; Pos GS: positive Gold Standard; Neg T: Negative test; Neg GS: Negative Gold standard; HIV: Human Immunodeficiency Virus, HBV: Hepatitis B Virus, HCV: Hepatitis C Virus; Sm: <i>Schistosoma mansoni</i> ; Sh: <i>Schistosoma haematobium</i> ; NS3: non-structural protein 3; PFR2: paraflagellar rod protein 2; KMP11: kinetoplastid membrane protein-11												

Table 2. Performance parameters of the 10 antigens tested in the multiplex assay on a reference panel of human samples

		2 SD cutoff				3 SD cutoff					AUC	
	Antigens	Pos T / Pos GS	Sensitivity	Neg T / Neg GS	Specificity	Correctly classified	Pos T / Pos GS	Sensitivity	Neg T / Neg GS	Specificity	Correctly classified	
HIV	p24	0/1	0	43/45	95.6	93.5	0/1	0	43/45	95.6	93.5	0-48 (1.00)
	gp41	1/1	100	39/45	86.7	87.0	0/1	0	44/45	97.8	95.7	0.92 (1.00)
HBV	HBV core	11/11	100	33/37	89.2	91.7	7/11	63.6	35/37	94.6	87.5	0.95 (0.90-1.00)
HCV	HCV core	-	-	46/48	95.8	-	-	-	4748	97.9	-	-
	HCV NS3	-	-	45/48	93.8	-	-	-	45/48	93.8	-	-
Chagas disease	PFR2	14/14	100	16/16	100	100	12/14	85.7	16/16	100	93.3	1.00 (1.00-1.00)
	KMP11	14/14	100	16/16	100	100	14/14	100	16/16	100	100	1.00 (1.00-1.00)
	Both	14/14	100	16/16	100	100	14/14	100	16/16	100	100	1.00 (1.00-1.00)
Strongyloides	NIE	5/6	83.3	33/38	86.8	86.4	4/6	66.7	37/38	97.4	93.2	0.88 (0.70-1.00)
<i>Schistosoma</i> spp	Sm - serpin	-	-	20/22	90.0	-		-	21/22	95.4	-	-
	Sh - serpin	-	-	18/22	81.8	-		-	21/22	95.4	-	-
	Both	-	-	18/22	81.8	-		-	21/22	95.4	-	-
Pos T: Positive test; Pos GS: Positive Gold Standard; Neg T: Negative test; Neg GS: Negative Gold standard; HIV: Human Immunodeficiency Virus, HBV: Hepatitis B Virus, HCV: Hepatitis C Virus; Sm: <i>Schistosoma mansoni</i> ; Sh: <i>Schistosoma haematobium</i> ; NS3: non-structural protein 3: PFR2: paraflagellar												

Table 3. Performance parameters of the 10 antigens tested in the multiplex assay in a prospective cohort of 48 migrant individuals with risk of exposure to the tested infections.

P rod protein 2; KMP11: kinetoplastid membrane protein-11

FIGURES

Figure 1. Dot plots showing the distribution of IgG levels measured against the 10 multiplexed antigens in the different panels of samples

1A. Panels of positive and negative control samples for each infection

1B. Panel of test samples from the migrants cohort

Legend:

The positive samples (1A) were selected based on seropositivity in the reference methods. In total, 40 positive samples were included for the respective infections (n=240).

Log10MFI: IgG serological levels (log10 mean fluorescence intensity); HBV: Hepatitis B

Virus, HCV: Hepatitis C Virus: Sm: Schistosoma mansoni; Sh: Schistosoma haematobium

Figure 2. Receiver operating curves for the 10 antigens tested in the multiplex assay to detect the infections.



LOGIOMFI



LOG10MFI

